文献速递肝病

评估抗生素在失代偿期肝硬化住院患者中的作用:ATTIRE 试验的启示

Evaluating the Role of Antibiotics in Patients Admitted to Hospital With Decompensated Cirrhosis: Lessons From the ATTIRE Trial.
PubMed 文献 · Am J Gastroenterol · 2022-08-12

基于 ATTIRE 试验数据,408 例入组时处方抗生素的患者中 203 例无感染,其病情较未用抗生素的无感染患者更重。抗生素治疗组与未用抗生素组后续医院获得性感染率无差异(19.2% vs 20.3%,P=0.83);倾向评分匹配后感染与死亡率均无差异。作者认为无感染诊断时半数抗生素未降低感染风险或改善死亡率。

要点

  • 入组时无感染者中,用抗生素组医院获得性感染 39/203(19.2%) vs 未用组 73/360(20.3%),P=0.83。
  • 倾向评分匹配后,抗生素组与未用组医院获得性感染或死亡率均无差异。
  • 作者建议若 24-48 小时无感染且病情改善,应根据培养敏感性及时降阶梯或停用抗生素。

核心结论

  • 入组时半数抗生素用于无感染诊断的患者,未降低总体医院获得性感染风险或改善死亡率。
  • 作者认为这支持在用药后 24-48 小时若无感染且病情改善,根据培养敏感性及时降阶梯或停用抗生素。

研究设计与样本

  • 基于 ATTIRE 试验数据,将基线无感染的 ATTIRE 患者按是否处方抗生素分组,研究试验治疗期间医院获得性感染与死亡率,并用倾向评分匹配校正疾病严重程度差异。

主要发现

  • 408 例入组时处方抗生素的患者中 203 例无感染,且病情较未用抗生素的无感染患者更重。
  • 抗生素治疗组后续医院获得性感染 39/203(19.2%),未用抗生素组 73/360(20.3%),P=0.83。
  • 抗生素治疗组 28 天死亡率更高(P=0.004),可能反映疾病严重程度增加;倾向评分匹配后两组医院获得性感染或死亡率均无差异。
  • 入组时无感染患者中,用或不用利福昔明者医院获得性感染(P=0.16)或死亡率均无差异,倾向匹配后结果一致。
  • 出院时接受长期抗生素预防者与未用抗生素者 6 个月死亡率无差异,尽管抗生素治疗患者入组时感染更多,但例数太少无法匹配。

局限性

  • 出院时接受长期抗生素预防的患者入组时感染更多,例数太少无法进行匹配。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Hospital-acquired infections (HAI) are common in cirrhosis with antibiotics frequently used to prevent infections, but their efficacy for this role is unknown. To investigate this, we used Albumin to Prevent Infection in Chronic Liver Failure (ATTIRE) data to evaluate whether antibiotic use in patients without infection prevented HAI. METHODS: In ATTIRE patients without infection at baseline grouped by antibiotic prescription or not, we studied HAI during trial treatment period and mortality, with propensity score matching to account for differences in disease severity. RESULTS: Two hundred three of 408 patients prescribed antibiotics at enrollment did not have infection and they were more unwell than noninfected patients not given antibiotics. There were no differences in subsequent HAI comparing antibiotic treated (39/203, 19.2%) to nonantibiotic treated (73/360, 20.3%; P = 0.83). Twenty-eight-day mortality was higher in antibiotic-treated patients ( P = 0.004) likely reflecting increased disease severity. Matching groups using propensity scoring revealed no differences in HAI or mortality. In noninfected patients at enrollment treated with/without rifaximin, there were no differences in HAI ( P = 0.16) or mortality, confirmed with propensity matching. Patients given long-term antibiotic prophylaxis at discharge had no differences in 6-month mortality compared with nonantibiotic patients, although antibiotic-treated patients had more infections at trial entry, with numbers too small for matching. DISCUSSION: Half of antibiotics at study entry were given to patients without an infection diagnosis which did not reduce the overall risk of HAI or improve mortality. This supports prompt de-escalation or discontinuation of antibiotics guided by culture sensitivities at 24-48 hours after commencement if no infection and the patient is improving.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Kutmutia R, Tittanegro T, China L, et al. Evaluating the Role of Antibiotics in Patients Admitted to Hospital With Decompensated Cirrhosis: Lessons From the ATTIRE Trial. Am J Gastroenterol. 2022. PMID: 35970815. doi:10.14309/ajg.0000000000001937

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。